Yvonne Efebera, MD
Enriched profileMedical Director, Blood and Marrow Transplant and Cellular Therapy Program · OhioHealth
Yvonne Efebera is Medical Director, Blood and Marrow Transplant and Cellular Therapy Program at OhioHealth. OpenAlex indexes 370 publications with 10,195 citations (h-index 43); ClinicalTrials.gov lists 6 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 14 Oct 2026
Yvonne Adeduni Efebera, MD, is Medical Director, Blood and Marrow Transplant and Cellular Therapy Program at OhioHealth (Arthur G. H. Bing Cancer Center, Blood and Marrow Transplant and Cellular Therapy Program), Columbus, OH. The public record shows 370 publications with 10,195 citations (h-index 43), centered on Hematology. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 22 companies, 1 NIH-funded awards (2013–2014).
- Most recent indexed publication: 2025 · Blood
- Top research focus: Hematology
- 6 registered trials on ClinicalTrials.gov
- Open Payments reporting from 22 companies
Generated from the cited public record · current as of 14 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 11 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 14 Oct 2026
Listed as an investigator on 6 registered studies on ClinicalTrials.gov. The most recent:
- Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Sponsor: Alliance Foundation Trials, LLC.
- Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma
Sponsor: Yvonne Efebera
- HDAC Inhibitor AR-42 and Pomalidomide in Treating Patients With Relapsed Multiple Myeloma
Sponsor: Ohio State University Comprehensive Cancer Center
Industry payments
Updated 14 Oct 2026
22 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20254 payments$17,695openpaymentsdata.cms.gov ↗
- Kite Pharma, Inc.Program year202510 payments$12,986openpaymentsdata.cms.gov ↗
- GENZYME CORPORATIONProgram year20254 payments$12,526openpaymentsdata.cms.gov ↗
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
22.8%Other nervous system drugs12.7%Vyndamax100%Part D<11 patientsGabapentinoids7%Gabapentin100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
21.1%Potassium supplement10.8%Potassium Chloride100%Part D≥17 patientsCorticosteroid4.1%Prednisone100%Part D<11 patients+ 2 more classes in this area
Anti-infectives
18.2%Short-acting sulfonamides14.6%Sulfamethoxazole-Trimethoprim100%Part D≥24 patientsHerpesvirus Nucleoside Analog DNA Polymerase Inhibitor3.5%Valacyclovir100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 14 Oct 2026
1 NIH research award on record, funded 2013–2014 per NIH RePORTER. The latest:
- MicroRNAs as biomarkers for acute graft-versus-host disease
Ohio State University
FY2014$113,190R21HL117707 - MicroRNAs as biomarkers for acute graft-versus-host disease
Ohio State University
FY2013$115,156R21HL117707
Publications
Updated 14 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
Online presence
Updated 14 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/yvonne-efebera-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/efebera-yvonne-41b67721
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - LinkedIn
linkedin.com/in/yvonne-efebera-48720288
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - ResearchGate
researchgate.net/profile/Yvonne-Efebera
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/EfeberaYvonne
- X / Twitter
x.com/efeberamd
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →x.com ↗
Mentions by others
where others cite or feature them- Other
cancer.osu.edu/blog/march-physician-of-the-month-yvonne-efebera
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.osu.edu ↗ - Other
cancer.osu.edu/find-a-doctor/search-physician-directory/yvonne-a-efebera
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancer.osu.edu ↗ - Other
onclive.com/authors/yvonne-efebera,-md,-ohio-state-university-comprehensive-cancer-center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - X / Twitter
x.com/OncLive/status/1889811721306444219
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 14 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →issuewire.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →issuewire.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →issuewire.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →issuewire.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →issuewire.com ↗
- Board Certified
Medical Oncology (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →issuewire.com ↗ - Board Certified
Internal Medicine (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →issuewire.com ↗
Editorial & leadership roles
journal and society appointments- Editorial Board
Journal of Hematology & Thrombosis
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →avensonline.org ↗
Awards & honors
honors on the public record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →issuewire.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →issuewire.com ↗
Secondary affiliations
appointments beyond the home institution- Assistant/Associate Professor of Medicine
Division of Hematology, The Ohio State University / Ohio State University Comprehensive Cancer Center (prior faculty affiliation)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
Media & interviews
press, podcasts and appearances- OncLive contributor/author page
multiple video segments and Peer Exchange panel discussions on multiple myeloma (e.g. "Introduction to Multiple Myeloma")
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Gary Ansel, MD
OhioHealth
Steven Yakubov, MD
OhioHealth
Nirav Vora, MD
OhioHealth
Subha Raman, MD
OhioHealth
Joseph Antin, MD
Boston University
Scott Kaufmann, MD
Mayo Clinic College of Medicine
Jeffrey Miller, MD
University of Minnesota Medical School
Ruben Mesa, MD
Atrium Health Wake Forest Baptist Comprehensive Cancer Center